179552-74-0 Usage
Description
N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-nitroquinazolin-4-aMine is a synthetic intermediate with significant applications in the pharmaceutical industry. It is characterized by its unique chemical structure, which includes a chloro-fluorophenyl group and a methoxy-nitroquinazolin-4-amine moiety. N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-nitroquinazolin-4-aMine plays a crucial role in the development of various therapeutic agents, particularly those targeting cancer and respiratory diseases.
Uses
Used in Pharmaceutical Industry:
N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-nitroquinazolin-4-aMine is used as a synthetic intermediate for the development of Afatinib (A355300), an aminocrotonylamino-substituted quinazoline derivative. N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-nitroquinazolin-4-aMine is specifically designed to target and inhibit certain protein receptors, such as the epidermal growth factor receptor (EGFR), which are often overexpressed in various types of cancer cells. By inhibiting these receptors, Afatinib can effectively suppress tumor growth and progression.
Used in Cancer Treatment:
N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-nitroquinazolin-4-aMine is used as a key component in the synthesis of Afatinib, which is employed for treating various types of cancer. These include diseases of the respiratory tract, lungs, gastrointestinal tract, bile duct, and gallbladder. The compound's ability to inhibit EGFR and other related receptors makes it a valuable asset in the fight against cancer, as it can help to reduce tumor size, slow down the spread of cancer cells, and improve the overall prognosis for patients.
Used in Respiratory Disease Treatment:
In addition to its applications in cancer treatment, N-(3-chloro-4-fluorophenyl)-7-Methoxy-6-nitroquinazolin-4-aMine is also utilized in the development of therapeutic agents for respiratory diseases. The compound's role in the synthesis of Afatinib allows for the creation of medications that can help to alleviate symptoms and improve the quality of life for patients suffering from respiratory conditions. By targeting the underlying causes of these diseases, such as inflammation and excessive mucus production, Afatinib can provide effective relief and support for those in need.
Check Digit Verification of cas no
The CAS Registry Mumber 179552-74-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,5,5 and 2 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 179552-74:
(8*1)+(7*7)+(6*9)+(5*5)+(4*5)+(3*2)+(2*7)+(1*4)=180
180 % 10 = 0
So 179552-74-0 is a valid CAS Registry Number.
179552-74-0Relevant articles and documents
Tyrosine kinase inhibitor and pharmaceutical application thereof
-
Paragraph 0019; 0021; 0026-0027, (2021/08/19)
The invention relates to a tyrosine kinase inhibitor containing a quinazoline derivative in the fields of tumor treatment medicines and the like, and application of the tyrosine kinase inhibitor in treatment medicines for inhibiting and treating diseases caused by overexpression of tyrosine kinase. The active ingredient of the tyrosine kinase inhibitor is a quinazoline derivative with a structure shown in the following formula: a functional group containing XCH2 (CH2) nC = O is introduced on the basis of a quinazoline structure, and the functional group is easily combined with cysteine sulfydryl through nucleophilic reaction to form a covalent bond so that the activity of tyrosine kinase is irreversibly inhibited.
Preparation method of dacotinib
-
Paragraph 0039-0042, (2022/01/10)
The present invention discloses a method of preparation of dacotinib, comprising the following steps: (N- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazoline) in a base / methanol system to undergo a methyl oxidation reaction, to compound 02 (N- (3-
EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE
-
Paragraph 00618; 0619, (2018/07/29)
The present disclosure relates to bifunctional compounds, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand which binds to an E3 ubiquitin ligase and on the other end a moiety which binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effectuate ubiquitination, and therefore, degradation (and inhibition) of the target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
